Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/05/22
Vir Biotechnology, Inc. (VIR) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 04/28/22
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D DayGlobeNewsWire • 04/27/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRPRNewsWire • 04/23/22
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022GlobeNewsWire • 04/21/22
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data ChallengeGlobeNewsWire • 04/06/22
Vir Biotechnology to Participate in the 21st Annual Needham Healthcare ConferenceGlobeNewsWire • 04/04/22
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?Zacks Investment Research • 03/31/22
Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600PRNewsWire • 03/29/22
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron SubvariantBenzinga • 03/28/22